3 Stocks Driving The Drugs Industry Higher

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 22 points (0.1%) at 16,756 as of Friday, June 13, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,558 issues advancing vs. 1,369 declining with 183 unchanged.

The Drugs industry currently sits down 0.4% versus the S&P 500, which is up 0.2%. Top gainers within the industry include Mylan ( MYL), up 1.0%, Actavis ( ACT), up 0.8% and Forest Laboratories ( FRX), up 0.6%. On the negative front, top decliners within the industry include United Therapeutics ( UTHR), down 4.0%, Novo Nordisk A/S ( NVO), down 1.6%, Biomarin Pharmaceutical ( BMRN), down 1.6%, Grifols ( GRFS), down 1.1% and Vertex Pharmaceuticals ( VRTX), down 0.9%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. Nektar Therapeutics ( NKTR) is one of the companies pushing the Drugs industry higher today. As of noon trading, Nektar Therapeutics is up $1.62 (12.9%) to $14.16 on heavy volume. Thus far, 2.9 million shares of Nektar Therapeutics exchanged hands as compared to its average daily volume of 1.2 million shares. The stock has ranged in price between $13.13-$14.65 after having opened the day at $13.50 as compared to the previous trading day's close of $12.54.

Nektar Therapeutics, a clinical-stage biopharmaceutical company, develops drug candidates that utilize its PEGylation and polymer conjugate technology platforms in the United States. Nektar Therapeutics has a market cap of $1.6 billion and is part of the health care sector. Shares are up 10.5% year-to-date as of the close of trading on Thursday. Currently there are 6 analysts who rate Nektar Therapeutics a buy, 1 analyst rates it a sell, and 1 rates it a hold.

TheStreet Ratings rates Nektar Therapeutics as a sell. Among the areas we feel are negative, one of the most important has been weak operating cash flow. Get the full Nektar Therapeutics Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Endo International ( ENDP) is up $0.84 (1.2%) to $68.59 on light volume. Thus far, 355,219 shares of Endo International exchanged hands as compared to its average daily volume of 3.0 million shares. The stock has ranged in price between $67.00-$68.63 after having opened the day at $67.95 as compared to the previous trading day's close of $67.75.

Endo International plc, a specialty healthcare company, develops, manufactures, markets, and distributes branded pharmaceutical and generic products, and medical devices worldwide. Endo International has a market cap of $10.3 billion and is part of the health care sector. Shares are up 0.4% year-to-date as of the close of trading on Thursday. Currently there are 8 analysts who rate Endo International a buy, 1 analyst rates it a sell, and 6 rate it a hold.

TheStreet Ratings rates Endo International as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, expanding profit margins and notable return on equity. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, weak operating cash flow and generally higher debt management risk. Get the full Endo International Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, AbbVie ( ABBV) is up $0.35 (0.7%) to $54.01 on light volume. Thus far, 1.5 million shares of AbbVie exchanged hands as compared to its average daily volume of 5.8 million shares. The stock has ranged in price between $53.44-$54.31 after having opened the day at $53.66 as compared to the previous trading day's close of $53.66.

AbbVie Inc., a research-based biopharmaceutical company, is engaged in the discovery, development, manufacture, and sale of pharmaceutical products worldwide. AbbVie has a market cap of $86.2 billion and is part of the health care sector. Shares are up 1.6% year-to-date as of the close of trading on Thursday. Currently there are 5 analysts who rate AbbVie a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates AbbVie as a hold. The company's strengths can be seen in multiple areas, such as its notable return on equity, revenue growth and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including weak operating cash flow and generally higher debt management risk. Get the full AbbVie Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).
null

If you liked this article you might like

3 Reasons Pfizer May Want to Buy Bristol-Myers Squibb

3 Reasons Pfizer May Want to Buy Bristol-Myers Squibb

Dow Soars Over 250 Points to Post Its Fourth Straight Day of Gains
Nektar Shares Surge on Bristol-Myers Collaboration

Nektar Shares Surge on Bristol-Myers Collaboration

10 Favorite Healthcare Stocks for 2018: Medical Marijuana to Opioid Treatment

10 Favorite Healthcare Stocks for 2018: Medical Marijuana to Opioid Treatment

Rev's Forum: Problems Simmer, but It's Still Too Early for a Bearish Bias

Rev's Forum: Problems Simmer, but It's Still Too Early for a Bearish Bias